Processing

Please wait...

PATENTSCOPE will be unavailable a few hours for maintenance reason on Tuesday 27.07.2021 at 12:00 PM CEST
Settings

Settings

Goto Application

1. WO2020142373 - METHODS AND MATERIALS FOR TREATING LEUKODYSTROPHIES

Publication Number WO/2020/142373
Publication Date 09.07.2020
International Application No. PCT/US2019/068731
International Filing Date 27.12.2019
IPC
A61K 31/519 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
495having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
519ortho- or peri-condensed with heterocyclic rings
A61K 38/16 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
A61P 25/28 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
25Drugs for disorders of the nervous system
28for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
C07K 14/00 2006.1
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
C07K 14/47 2006.1
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435from animals; from humans
46from vertebrates
47from mammals
C07K 14/705 2006.1
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435from animals; from humans
705Receptors; Cell surface antigens; Cell surface determinants
CPC
A61K 2039/545
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
545characterised by the dose, timing or administration schedule
A61P 25/28
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
25Drugs for disorders of the nervous system
28for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
C07K 14/585
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435from animals; from humans
575Hormones
585Calcitonins
C07K 16/18
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
C07K 16/2869
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
2869against hormone receptors
C07K 2317/21
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
2317Immunoglobulins specific features
20characterized by taxonomic origin
21from primates, e.g. man
Applicants
  • MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH [US]/[US]
Inventors
  • MESCHIA, James F.
Agents
  • WILLIS, Margaret S. J.
  • FINN III, J. Patrick
Priority Data
62/787,59402.01.2019US
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) METHODS AND MATERIALS FOR TREATING LEUKODYSTROPHIES
(FR) MÉTHODES ET MATÉRIELS PERMETTANT LE TRAITEMENT DE LEUCODYSTROPHIES
Abstract
(EN)
This document relates to methods and materials for treating a leukodystrophy (e.g., cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy; CADASIL). For example, one or more calcitonin gene-related peptide (CGRP) inhibitors can be administered to a mammal having, or at risk of developing, CADASIL to treat the mammal.
(FR)
L'invention concerne des méthodes et des matériels permettant le traitement de leucodystrophies (par exemple une artériopathie cérébrale autosomique dominante avec infarctus sous-corticaux et leucoencéphalopathie, ou CADASIL). Par exemple, un ou plusieurs inhibiteurs du peptide relié au gène calcitonine (CGRP) peuvent être administrés à un mammifère atteint de CADASIL, ou à risque de développer une CADASIL, afin de traiter le mammifère.
Latest bibliographic data on file with the International Bureau